Microbial Landscape of the Respiratory Tract of Children with Cystic Fibrosis: Monitoring Results

Mukhametzyanov A. M.
Doctor of Medicine, Chief Physician¹; Assistant Professor, Head, Chair for Epidemiology²

Kaydanek T. V.
MD, PhD, Assistant Professor, Chair for Epidemiology²

Latypov A. A.
Clinical Resident, Chair for Epidemiology²

Valeeva D. S.
Deputy Chief Physician³

Ponomareva D. N.
MD, Epidemiologist³

Ermolenko I. A.
MD, Pulmonologist³

Gazizova A. G.
MD, Bacteriologist³

1 - Republican Clinical Infectious Diseases Hospital, Ufa, Russian Federation
2 - Bashkir State Medical University, Ufa, Russian Federation
3 - Republican Pediatric Clinical Hospital, Ufa, Russian Federation

Latypov Almaz Ayratovich; e-mail: almaz.latup@mail.ru

None declared.

The study had no sponsorship.

Background. The article presents the results of microbiological monitoring of microorganisms of the respiratory tract of patients with cystic fibrosis (CF), changes in the spectrum, palette, and antibacterial resistance during repeated hospitalizations in a specialized hospital. Purpose of the study. To analyze the results of microbiological examination of respiratory tract biomaterial of children with CF hospitalized in a multidisciplinary pediatric hospital to optimize epidemiological surveillance at the local level. Materials and methods. The material for the study was the results of a microbiological study of smears from the pharynx, nose, or induced sputum of patients with cystic fibrosis observed at the Children's Center for Cystic Fibrosis (CF). Identification of isolated cultures was carried out by classical bacteriological methods. Subsequently, the isolated microorganisms were systematized to species. The analysis was carried out for 2019-2023. Determination of sensitivity to antibacterial drugs was carried out using the disk diffusion method. Indicators of the frequency (%) of isolation of various microorganisms and the frequency (%) of resistant microorganisms to the antimicrobial drugs used in a medical organization (MO) were calculated. A comparison was made of the frequency (%) and spectrum of isolated cultures during initial and subsequent hospitalizations at the Children's Cystic Fibrosis Center. Confidence intervals CI (95%) were calculated for relative values. Calculations were carried out using the epidemiological calculator Confidence Interval Calculator. Results. In the structure of isolated cultures from the biomaterial of the respiratory tract of children with cystic fibrosis, 45.4% were gram-negative microorganisms. During initial and subsequent hospitalizations, the highest frequency of isolation were Pseudomonas aeruginosa, Klebsiella pneumoniae, Stenotrophomonas maltophilia. Gram-positive microorganisms in the spectrum of isolated cultures amounted to 37.9%. The majority of the isolated gram-positive microorganisms are represented by Staphylococcus aureus (75.7%). During repeated hospitalizations to the Children's CF Center, based on the monitoring results, changes in the spectrum, frequency of isolation, and spectrum of resistance to antimicrobial drugs were determined. An increase in the frequency (p<0.05) of the isolation of Pseudomonas aeruginosa and Staphylococcus aureus was determined. During repeated hospitalizations, the frequency of isolation of associations of microorganisms increased from 50.5% CI [55.7; 45.3] to 81.4% CI [83.8; 79.0] (p<0.05). An increase in the frequency (p<0.05) of isolation of Pseudomonas aeruginosa strains resistant to reserve antibacterial drugs was determined by 3.2 times during subsequent hospitalizations. Conclusion. The revealed changes in the spectrum, frequency, palette and antibiotic resistance of microorganisms of the respiratory tract of CF patients at the local level of epidemiological surveillance indicate the need to develop algorithms of action in outpatient and inpatient management of CF patients to ensure epidemiologic safety of medical activity and improve the quality of medical care.

Cystic fibrosis, microbiological monitoring, chronic lung infection, antibiotic resistance, epidemiological risk, epidemiological surveillance

10.29234/2308-9113-2024-12-4-43-59

1. Kapranova N.I., Kashirskoy N.Yu. Mukoviscidoz. [Cystic fibrosis.] Moscow: Medpractika-M, 2014. (In Russ.)

2. Chernukha M.Yu., Shaginyan I.A. Mikrobiologiya hronicheskoj infekcii legkih u bol'nyh mukoviscidozom. Mukoviscidoz. [Microbiology of chronic lung infection in patients with cystic fibrosis. Cystic Fibrosis.] Moscow: Medpractika-M, 2014. P. 116-148. (In Russ.)

3. Baranov A.A., Namazova-Baranova L.S., Kutsev S.I., Avdeev S.N., Polevichenko E.V., Belevsky A.S., et al. Sovremennye podhody k vedeniyu detej s mukoviscidozom. [Modern approaches to the management of children with cystic fibrosis.] Pediatricheskaya farmakologiya [Pediatric Pharmacology] 2022; 19(2): 153-195. (In Russ.)

4. Goryainova A.V., Shumilov P.V., Kashirskaya N.Yu., Semyk S.Yu. Rol' displazii soedinitel'noj tkani v techenii mukoviscidoza u detej. Kliniko-geneticheskie aspekty. [The role of connective tissue dysplasia in the course of cystic fibrosis in children. Clinical and genetic aspects.] Rossijskij vestnik perinatologii i pediatrii [Russian Bulletin of Perinatology and Pediatrics] 2018; 63(5): 20-28. (In Russ.)

5. Lopes-Pacheco M. CFTR modulators: Shedding light on precision medicine for cystic fibrosis. Front Pharmacol 2016; (7): 275, doi: 10.3389/fphar.2016.00275

6. Avetisyan L.R., Chernukha M.Yu., Shaginyan I.A., et al. Antibiotikochuvstvitel'nost' Staphylococcus aureus, Pseudomonas aeruginosa i bakterij Burkholderia cepacia complex, persistiruyushchih v legkih bol'nyh mukoviscidozom. [Antibiotic sensitivity of Staphylococcus aureus, Pseudomonas aeruginosa and Burkholderia cepacia complex bacteria persisting in the lungs of patients with cystic fibrosis.] Zhurnal epidemiologii, mikrobiologii i immunologii [Journal of Epidemiology, Microbiology and Immunology] 2015; (6): 3-10. (In Russ.)

7. De Boeck K. Cystic fibrosis in the year 2020: disease with a new face. Acta Paediatr 2020; 109(5): 893-899, doi: 10.1111/apa.15155

8. Shaginyan I.A., Chernukha M.Yu., Avetisyan L.R., et al. Epidemiologicheskie osobennosti hronicheskoj infekcii legkih u bol'nyh mukoviscidozom. [Epidemiological features of chronic lung infection in patients with cystic fibrosis.] Epidemiologiya i vakcinoprofilaktika [Epidemiology and Vaccinal Prevention] 2017; 16 (6): 5-13. (In Russ.)

9. Avetisyan L.R., Chernukha M.Yu., Zhukhovitsky V.G., Rusakova E.V., Burmistrov E.M., Medvedeva O.S., et al. Mikrobiologicheskij monitoring hronicheskoj infekcii legkih, vyzvannoj Achromobacter SPP., u pacientov s mukoviscidozom. [Microbiological monitoring of chronic lung infection caused by Achromobacter spp., in patients with cystic fibrosis.] Voprosy prakticheskoj pediatrii [Questions of practical pediatrics] 2022; 17(3): 26-32. (In Russ.)

10. Stahl M., Steinke E., Mall M.A. Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes (Basel) 2021; 12(6): 803, doi: 10.3390/genes12060803.

11. Baranov A.A., Namazova-Baranova L.S., Kutsev S.I., et al. Kistoznyj fibroz (mukoviscidoz). Klinicheskie rekomendacii. [Clinical guidelines «Cystic fibrosis».] Moscow, 2020. (In Russ.)

12. Kalyuk A.N. Metody bakteriologicheskogo issledovaniya uslovno-patogennyh mikroorganizmov v klinicheskoj mikrobiologii. [Methods of bacteriological research of opportunistic microorganisms in clinical microbiology.] Metodicheskie rekomendacii Minzdrava RSFSR. [Methodological recommendations of the Ministry of Health of the RSFSR.] Moscow, 1991. (In Russ.)

13. Becker S.L., Berger F.K., Feldner S.K., Karliova I., Haber M., Mellmann A., Schäfers H.-J., Gärtner B. Outbreak of Burkholderia cepacia complex infections associated with contaminated octenidine mouthwash solution, Germany, August to September 2018. Euro Surveill. 2018; 23(42): 1800540, doi: 10.2807/1560-7917.ES.2018.23.42.1800540

14. Shaban R.Z., Sotomayor-Castillo C., Nahidi S., Li C., Macbeth D., Mitchell B.G., Russo P.L. Global burden, point sources, and outbreak management of healthcare-associated Burkholderia cepacia infections: An integrative review. Infect Control Hosp Epidemiol 2020; 41(7): 777-783, doi: 10.1017/ice.2020.184

15. Ob organizacii sistemy lokal'nogo monitoringa antimikrobnoj rezistentnosti. [On the organization of a system for local monitoring of antimicrobial resistance.] Pis'mo Minzdrava Rossii ot 25.05.2023 N 30-5/I/2-9190. [Letter of the Ministry of Health of Russia of May 25, 2023 N 30-5/I/2-9190.] (In Russ.)

16. Schaffer K. Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect 2015; 89(4): 309-313, doi: 10.1016/j.jhin.2015.02.005

17. Krasovsky S.A., Adyan T.A., Amelina E.L., Sergienko D.F., Shadrina V.V., Gushchin M.Yu., Zonenko O.G., Makarova M.A. Cystic fibrosis: some issues of epidemiology and genetics. [Mukoviscidoz: nekotorye voprosy epidemiologii i genetiki.] Prakticheskaya pul'monologiya [Practical pulmonology] 2019; (4): 45-50. (In Russ.)

18. Feldblum I.V., Koza N.M. Review on: Shkarin V.V., Kovalishena O.V. Novye infekcii: sistematizaciya, problemy, perspektivy. [New infections: systematization, problems, prospects.] Zhurnal mikrobiologii [Journal of Microbiology] 2013, (4): 118-120. (In Russ.)

19. Minulin I.B., Shvabsky O.R., Ivanov I.V., Matytsin N.O., Shcheblykina A.A., Taut D.F. Obzor podhodov k uchetu i analizu nezhelatel'nyh sobytij pri osushchestvleniii medicinskoj deyatel'nosti. [Review of approaches to recording and analyzing adverse events in medical activities.] Menedzher zdravoohraneniya [Healthcare Manager] 2021; (3): 9-12.